# DAWN-303 (NCT07522073)

> A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07522073
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Solid Tumors
- Interventions: INCB161734; Placebo; Investigator's choice of chemotherapy
- Enrollment: 588
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free survival (PFS) by BICR
- Primary outcome: Objective Response by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dawn-303-nct07522073